Vor Biopharma Inc. (NYSE:VOR) Receives $7.06 Average PT from Brokerages

Shares of Vor Biopharma Inc. (NYSE:VOR) have been assigned an average rating of “Hold” from the ten research firms that are covering the company, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $7.06.

A number of research analysts have weighed in on the company. JMP Securities reaffirmed a “market perform” rating and set a $6.00 target price on shares of Vor Biopharma in a report on Friday, May 9th. Stifel Nicolaus cut their price objective on Vor Biopharma from $12.00 to $5.00 and set a “buy” rating for the company in a report on Friday, March 21st. Jones Trading cut shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Citizens Jmp lowered shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 9th. Finally, Wedbush reiterated a “neutral” rating and issued a $0.40 target price (down from $7.00) on shares of Vor Biopharma in a research report on Thursday, May 8th.

Vor Biopharma Stock Performance

Shares of NYSE VOR opened at $0.22 on Tuesday. The stock has a market cap of $27.70 million, a PE ratio of -0.13 and a beta of -0.51. Vor Biopharma has a fifty-two week low of $0.13 and a fifty-two week high of $1.80. The stock has a fifty day moving average of $0.40 and a 200-day moving average of $0.86.

Institutional Trading of Vor Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in Vor Biopharma during the 1st quarter valued at about $140,000. Goldman Sachs Group Inc. boosted its position in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares during the period. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma during the 1st quarter valued at $100,000. Money Concepts Capital Corp boosted its position in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after buying an additional 26,535 shares during the period. Finally, Two Sigma Investments LP boosted its position in Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after buying an additional 25,930 shares during the period. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.